Leeds medtech Tissue Regenix Group has signed an exclusive distribution deal for its OrthoPure XT product in Germany.
Hamburg-based 2med specialises in products for the surgical and orthobiological treatments of the musculoskeletal system, and will now distribute Tissue Regenix’s OrthoPure XT, a patented dCell artificial ligament technology which is used in cruciate and knee ligament reconstruction.
Initially the multi-year deal covers only Germany but there is potential for expansion into other territories that 2med covers.
Daniel Lee, chief executive officer of Tissue Regenix Group, said: “Following the success of our partnership with Geistlich Biomaterials Italia, announced in March 2022, we are pleased to have signed this distribution agreement with 2med for Germany. 2med’s work with doctors and patients to offer advanced treatments and minimise rehabilitation times are aligned with this innovative product and has made 2med one of the leading specialist dealers in Germany. We look forward to working with 2med and continuing to expand the use of OrthoPure XT across Europe.”
